The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Proponents say direct-to-consumer sales by drugmakers cut out intermediaries that add needlessly to prices. Detractors see ...

From 1 July, the weight-loss drug Wegovy will become available from Belgian pharmacists on prescription. This means Wegovy is ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Due to popularity of the medications, GLP-1s were in short supply up until recently. Obesity is a common issue among ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...

Creative Financial Designs Inc. ADV lessened its holdings in Novo Nordisk A/S (NYSE:NVO – Free Report) by 83.5% during the first quarter, according to its most recent filing with the Securities and ...

Semaglutide manufacturers seem to be taking advantage of America’s health crises to indulge in anticompetitive behavior.

China has approved a new weight-loss drug that is poised to rival Novo Nordisk and Eli Lilly's popular GLP-1 treatments, ...

Novo Nordisk AS and a group of insurers will pay $32 million to end litigation over its $1.8 billion acquisition of ...

Lifestyle therapy may not be enough to improve outcomes for patients with HF and obesity, but careful risk evaluation and ...